Attention to the Unseen

STAT reports: The Omicron wave in the United States is upon us. If you were fortunate enough to tune out from Covid-19 news over the holidays, you’re coming back to startling reports about record high case counts and, in some places, increases in hospitalizations. The wave will crest, of course; the question is when. For now, experts say, the country still has a ways to go to get through the Omicron surge. Below, STAT outlines what Omicron is already teaching…

Read More Read More

The Wall Street Journal reports: The Food and Drug Administration last week authorized two oral antiviral medicines for the early treatment of Covid-19. But don’t get too excited. The U.S. will still have a meager treatment arsenal this winter. The U.S. has been relying on monoclonal-antibody treatments, but most don’t hold up against the Omicron variant. One, by GlaxoSmithKline and Vir Biotechnology, does better at neutralizing the variant, but supply is limited. Pfizer’s newly authorized antiviral pack Paxlovid will also…

Read More Read More

STAT reports: With the world facing the latest in a seemingly endless stream of coronavirus variants — and with bullish talk from manufacturers about a need for even more vaccine shots — you wouldn’t be alone if you were wondering: Are Covid boosters always going to be a fixture in our future? The simple truth is that, at this point, there’s no definitive answer to that question. But virologists, immunologists, and vaccinologists have opinions that are anchored in an understanding…

Read More Read More

Dhruv Khullar writes: The Covid-19 pandemic, like every pandemic before it, is a story of equilibriums: between viral biology and human immune response; between news of the pathogen and fear of it; between the damage it inflicts and the social, economic, and political choices we make. A disease persists as a pandemic as long as these forces remain in flux; it becomes endemic when the balance is, more or less, set. The morning after Thanksgiving, Americans awoke to an unsettling…

Read More Read More

Bloomberg reports: A two-shot course of Pfizer Inc.’s vaccine has just 22.5% efficacy against symptomatic infection with the omicron variant, but can thwart severe disease, according to laboratory experiments in South Africa. Researchers at the Africa Health Research Institute in Durban issued additional data on a small study released earlier this week. The research considered blood plasma samples from 12 participants. Scientists found omicron resulted in about a 41-fold reduction in levels of neutralizing antibodies produced by people who had…

Read More Read More

The New York Times reports: From the start of the pandemic, the coronavirus seemed to target people carrying extra pounds. Patients who were overweight or obese were more likely to develop severe Covid-19 and more likely to die. Though these patients often have health conditions like diabetes that compound their risk, scientists have become increasingly convinced that their vulnerability has something to do with obesity itself. Now researchers have found that the coronavirus infects both fat cells and certain immune…

Read More Read More

Nature reports: As the world sped towards a pandemic in early 2020, evolutionary biologist Jesse Bloom gazed into the future of SARS-CoV-2. Like many virus specialists at the time, he predicted that the new pathogen would not be eradicated. Rather, it would become endemic — the fifth coronavirus to permanently establish itself in humans, alongside four ‘seasonal’ coronaviruses that cause relatively mild colds and have been circulating in humans for decades or more. Bloom, who is based at the Fred…

Read More Read More

Science reports: Since South African scientists announced last week they had identified an unsettling new variant of SARS-CoV-2, the world has anxiously awaited clues about how it might change the trajectory of the pandemic. But as big a mystery—if less urgent—is where and how Omicron evolved, and what lessons its emergence holds for avoiding future dangerous variants. Omicron clearly did not develop out of one of the earlier variants of concern, such as Alpha or Delta. Instead, it appears to…

Read More Read More

A virus’s genes hold a record of where it’s traveled, and when. imaginima/E+ via Getty Images By Claire Guinat, Swiss Federal Institute of Technology Zurich; Etthel Windels, Swiss Federal Institute of Technology Zurich, and Sarah Nadeau, Swiss Federal Institute of Technology Zurich More than 250 million people worldwide have tested positive for SARS-CoV-2, usually after a diagnostic nose swab. Those swabs aren’t trash once they’ve delivered their positive result, though. For scientists like us they carry additional valuable information about…

Read More Read More

The Wall Street Journal reports: The Omicron variant of the Covid-19 virus could lead to more infections among vaccinated people, according to several scientists, but some said there were reasons to believe the shots would protect against severe disease. While the new variant might evade the antibodies generated in reaction to the vaccines, the virus will likely remain vulnerable to immune cells that destroy it once it enters the body, said Ugur Sahin, co-founder of BioNTech SE, which sells a…

Read More Read More

AP Photo/Denis Farrell By Hamish McCallum, Griffith University These are very early days in terms of our understanding the Omicron variant. What is known is that it has a large number of mutations, particularly in the spike protein and it appears to be rapidly spreading in specific parts of the world. Very early indications from Africa suggest it does not cause particularly severe disease (though the World Health Organization has urged caution given the limited data available). At this point,…

Read More Read More